Skip to Main Content

After being kept under wraps for a year, an expansive review of European regulations designed to spur development of drugs for rare diseases and children found the number of medicines has increased. But at the same time, drug makers often did not address some of the most urgent needs.

Instead, the pharmaceutical industry sometimes targeted more profitable therapeutic areas, raising questions about whether incentives offered to the pharmaceutical industry should be changed, according to the long-awaited report from the European Commission. As in the U.S., these incentives include market exclusivity for a period of time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • May one observe that any report whose summary is 109 pages should be read on its own?
    “As noted, this is a lengthy report, which we encourage you to scour for more details and insights. There is also this 109-page summary.”
    Put it another way, is it a summary or … a sequel?

    • Dear Observer079

      Tis the summertime which, for some, calls for light reading.

      Enjoy,
      ed at pharmalot

Comments are closed.